CURACEF DUO, 50 MG/ML / 150 MG/ML, SUSPENSION FOR CATTLE

Riik: Iirimaa

keel: inglise

Allikas: HPRA (Health Products Regulatory Authority)

Toimeaine:

CEFTIOFUR (AS HYDROCHLORIDE), KETOPROFEN

Saadav alates:

Virbac S.A.

ATC kood:

QJ01DD

INN (Rahvusvaheline Nimetus):

CEFTIOFUR (AS HYDROCHLORIDE), KETOPROFEN

Annus:

50/150

Ravimvorm:

Suspension for Injection

Retsepti tüüp:

POM

Terapeutiline rühm:

Bovine

Terapeutiline ala:

Third-generation cephalosporins

Näidustused:

Antibacterial

Volitamisolek:

Authorised

Loa andmise kuupäev:

2014-08-01

Toote omadused

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Curacef duo, 50 mg/ml / 150 mg/ml, Suspension for Injection for Cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains
ACTIVE SUBSTANCES:
Ceftiofur (as hydrochloride)
50.0
mg
Ketoprofen
150.0 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Suspension for injection.
Off - white to pinkish suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of bovine respiratory disease (BRD) caused by _Mannheimia haemolytica _and _Pasteurella multocida_
susceptible to ceftiofur and the reduction of associated clinical signs of inflammation or pyrexia.
4.3 CONTRAINDICATIONS
Do not use in cases of known resistance to other cephalosporins or beta-lactam antibiotics.
Do not use in case of hypersensitivity to ceftiofur and other -lactam antibiotics.
Do not use in case of hypersensitivity to ketoprofen.
Do not use in poultry (including eggs) due to risk of spread of antimicrobial resistance to humans.
Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently or within 24 hours of each
other.
Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of
gastro-intestinal ulceration or bleeding, where there is evidence of a blood dyscrasia.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal
toxicity.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 12/08/2016_
_CRN 7024198_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
I) SPECIAL P